AbCellera Biologics Inc. Comprehensive Income
AbCellera Biologics Inc. (ABCL) reported Comprehensive Income of -$56.16 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-05
- AbCellera Biologics Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$56.16M.
- AbCellera Biologics Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$41.35M.
- AbCellera Biologics Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$10.48M.
- AbCellera Biologics Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$57.16M.
- AbCellera Biologics Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$146.27M.
- AbCellera Biologics Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$165.51M.
- AbCellera Biologics Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$146.73M, a 193.55% decline from fiscal 2022.
- AbCellera Biologics Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was $156.85M, a 2.02% increase from fiscal 2021.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$56.16M 10-Q · filed 2026-08-05 | -$97.51M 10-Q · filed 2026-08-05 | -$107.99M derived: sum of 3 quarters · filed 2026-08-05 | -$165.15M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$41.35M 10-Q · filed 2026-05-11 | -$51.83M derived: sum of 2 quarters · filed 2026-05-11 | -$108.99M derived: sum of 3 quarters · filed 2026-05-11 | -$139.38M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$10.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$67.64M derived: sum of 2 quarters · filed 2026-02-24 | -$98.03M derived: sum of 3 quarters · filed 2026-08-05 | -$146.27M 10-K · filed 2026-02-24 |
| 2025-09-30 | -$57.16M 10-Q · filed 2025-11-06 | -$87.55M derived: sum of 2 quarters · filed 2026-08-05 | -$135.79M 10-Q · filed 2025-11-06 | -$173.14M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$30.39M 10-Q · filed 2026-08-05 | -$78.63M 10-Q · filed 2026-08-05 | -$115.98M derived: sum of 3 quarters · filed 2026-08-05 | -$166.25M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$48.24M 10-Q · filed 2026-05-11 | -$85.60M derived: sum of 2 quarters · filed 2026-05-11 | -$135.86M derived: sum of 3 quarters · filed 2026-05-11 | -$173.05M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$37.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$87.62M derived: sum of 2 quarters · filed 2026-02-24 | -$124.81M derived: sum of 3 quarters · filed 2026-02-24 | -$165.51M 10-K · filed 2026-02-24 |
| 2024-09-30 | -$50.27M 10-Q · filed 2025-11-06 | -$87.45M derived: sum of 2 quarters · filed 2025-11-06 | -$128.16M 10-Q · filed 2025-11-06 | -$175.57M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | -$37.19M 10-Q · filed 2025-08-07 | -$77.89M 10-Q · filed 2025-08-07 | -$125.30M derived: sum of 3 quarters · filed 2026-02-24 | -$153.47M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | -$40.71M 10-Q · filed 2025-05-08 | -$88.12M derived: sum of 2 quarters · filed 2026-02-24 | -$116.29M derived: sum of 3 quarters · filed 2026-02-24 | -$146.69M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | -$47.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$75.58M derived: sum of 2 quarters · filed 2026-02-24 | -$105.99M derived: sum of 3 quarters · filed 2026-02-24 | -$146.73M 10-K · filed 2026-02-24 |
| 2023-09-30 | -$28.17M 10-Q · filed 2024-11-04 | -$58.58M derived: sum of 2 quarters · filed 2024-11-04 | -$99.32M 10-Q · filed 2024-11-04 | -$129.88M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$30.41M 10-Q · filed 2024-08-06 | -$71.15M 10-Q · filed 2024-08-06 | -$101.71M derived: sum of 3 quarters · filed 2025-02-27 | -$76.38M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$40.74M 10-Q · filed 2024-05-07 | -$71.31M derived: sum of 2 quarters · filed 2025-02-27 | -$45.98M derived: sum of 3 quarters · filed 2025-02-27 | -$52.97M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$30.57M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$5.24M derived: sum of 2 quarters · filed 2025-02-27 | -$12.23M derived: sum of 3 quarters · filed 2025-02-27 | $156.85M 10-K · filed 2025-02-27 |
| 2022-09-30 | $25.33M 10-Q · filed 2023-11-02 | $18.34M derived: sum of 2 quarters · filed 2023-11-02 | $187.41M 10-Q · filed 2023-11-02 | $247.00M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | -$7.00M 10-Q · filed 2023-08-03 | $162.08M 10-Q · filed 2023-08-03 | $221.67M derived: sum of 3 quarters · filed 2024-02-20 | $198.78M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $169.08M 10-Q · filed 2023-05-04 | $228.66M derived: sum of 2 quarters · filed 2024-02-20 | $205.78M derived: sum of 3 quarters · filed 2024-02-20 | $205.60M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $59.58M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $36.70M derived: sum of 2 quarters · filed 2024-02-20 | $36.52M derived: sum of 3 quarters · filed 2024-02-20 | $153.74M 10-K · filed 2024-02-20 |
| 2021-09-30 | -$22.89M 10-Q · filed 2022-11-08 | -$23.06M derived: sum of 2 quarters · filed 2022-11-08 | $94.16M 10-Q · filed 2022-11-08 | $211.16M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | -$171.00K 10-Q · filed 2022-08-09 | $117.05M 10-Q · filed 2022-08-09 | $234.05M derived: sum of 3 quarters · filed 2023-02-21 | $231.36M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $117.22M 10-Q · filed 2022-05-10 | $234.22M derived: sum of 2 quarters · filed 2023-02-21 | $231.53M derived: sum of 3 quarters · filed 2023-02-21 | $238.23M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $117.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $114.31M derived: sum of 2 quarters · filed 2023-02-21 | $121.01M derived: sum of 3 quarters · filed 2023-02-21 | $118.92M 10-K · filed 2023-02-21 |
| 2020-09-30 | -$2.69M 10-Q · filed 2021-11-10 | $4.01M derived: sum of 2 quarters · filed 2021-11-10 | $1.92M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $6.70M 10-Q · filed 2021-08-13 | $4.61M 10-Q · filed 2021-08-13 | ||
| 2019-12-31 | -$2.21M 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |